Company is participating in the lucrative $70B global in Vitro Diagnostics Market. This disruptive platform technology will radically change the current standard of diagnostics; the use of antibodies, that was introduced 40-50 years ago but are expensive, require controlled storage conditions and complicated sample workup limiting their usage worldwide. Alternatively PhageTech's sensors will be low cost, provide instant results, be convenient (used directly with any bodily fluid), and are highly sensitive and selective for disease biomarkers; even several at a time.